Abbott Laboratories stock holds firm after July earnings
Published on 09/08/2026 at 10:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Abbott Laboratories stock (ISIN US0028241000) is anchored by Q2 2026 figures from July 16, 2026: revenue rose 13.0 percent year over year to USD 12.59 billion, and EPS came in at USD 1.31, above the USD 1.28 consensus by USD 0.03.MarketBeat The same report shows net margin at 11.65 percent and return on equity at 17.69 percent.
Guidance stays in view
The market is also watching Abbott's Q3 2026 guidance of USD 1.38 to USD 1.46 EPS and FY 2026 guidance of USD 5.45 to USD 5.60 EPS, both still current for the latest reporting cycle.MarketBeat That makes the next quarter the key test: even a midpoint of USD 1.42 would sit above the Q2 print of USD 1.31 by USD 0.11.
Valuation near the top end
Abbott Laboratories has a market capitalization of USD 187.38 billion and a 52-week range of USD 81.97 to USD 137.49 as of September 8, 2026.MarketBeat At that scale, the stock is trading closer to the high than the low, with a spread of USD 55.52 between the two range points.
Diagnostics and devices
The company's latest report still points to a broad operating base, with revenue up 13.0 percent and margins holding above 11 percent in Q2 2026.MarketBeat That mix matters for Abbott's diagnostics and device portfolio, where a revenue beat of USD 70 million versus consensus can matter more than a small daily swing.
Price and listing
Abbott Laboratories stock trades on the NYSE under ticker ABT in USD. MarketBeat lists the company's market cap at USD 187.38 billion and its 52-week band at USD 81.97 to USD 137.49 as of September 8, 2026.MarketBeat
Abbott Laboratories stock overview
- Company: Abbott Laboratories
- ISIN: US0028241000
- Ticker: ABT
- Trading venue: NYSE
- Market capitalization: USD 187.38 billion (as of September 8, 2026)
- Sector / Industry: Health Care / Health Care Equipment
- Index membership: S&P 500
